VANCOUVER, British Columbia--(BUSINESS WIRE)--Aug. 10, 2006--InNexus Biotechnology Inc. (OTCBB: IXSBF) (TSX VENTURE: IXS), an innovative antibody-driven drug development company based on SuperAntibody(TM) Technologies, is pleased to announce today the full subscription of a non-brokered private placement. Major participating investors included SDS Capital of Greenwich, Conn., and RAB Capital of London, England. The funding will be used to advance the completion of one or more monetized partnerships for InNexus’ SuperAntibody Technology and initiate development of a lead SuperAntibody therapeutic candidate.
